FATE
Fate Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.48
+2.48%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
Market Cap
$297.15M
MomentumView details →
1D Return
+2.48%
YTD Return
+149.85%
RSI (14)
47.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
Market Cap
$297.15M
RSI (14)
47.0
MomentumView details →
1D Return
+2.48%
YTD Return
+149.85%
SummaryUpdated Jun 1, 2026
Fate Therapeutics, Inc. (NASDAQ:FATE) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in San Diego, California. The company went public in 2013 and has established itself as a pioneer in developing off-the-shelf cellular immunotherapies derived from induced pluripotent stem cells (iPSCs). Fate Therapeutics focuses on creating programmed cellular treatments for cancer and autoimmune disorders, representing a cutting-edge approach to cell therapy that could potentially transform how these diseases are treated.
Similar companies
Latest newsMore news →
Fate Therapeutics reported a Q2 2026 loss of $0.25 per share, beating the Zacks Consensus Estimate of a $0.28 loss and improving from a $0.29 loss a year earlier.22d agoFate Therapeutics dosed the first lupus nephritis patient in its Phase 2 potentially registrational trial RECLAIM-LN, utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy, with the patient treated as an outpatient with same-day discharge.23d ago